Skip to main content
    S

    Stryker Corporation (SYK)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $310.67
    +1.03 (+0.33%)

    Market Cap: $117.88B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Stryker Corporation (SYK) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Stryker (SYK) is expected to report earnings on Jan 27, 2027. In the quarter ended Sep 30, 2026, Stryker reported EPS of $3.52, below the $3.56 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    83%(33/40)
    Avg Surprise
    +3.45%

    Upcoming Estimates

    Reports Jan 27, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$5.06
    Range$4.55 - $5.30
    28 analysts
    Revenue Consensus
    $7.76B
    Range$7.42B - $8.16B
    28 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$3.18
    Range$2.83 - $3.63
    16 analysts
    EPS Revisions
    1
    9
    30d
    EPS Estimate DriftChange to current
    90d ago$3.30-3.7%
    60d ago$3.29-3.2%
    30d ago$3.28-3.0%
    7d ago$3.180.0%
    Current$3.18
    Revenue Consensus
    $6.52B
    Range$6.41B - $6.68B
    14 analysts

    Next Report

    SYK has an expected report date of Jan 27, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.2% above the $4.47 reported for the quarter ended Dec 31, 2025.

    SYK Earnings Call

    The latest SYK earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, SYK beat 33 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $6.52B, up 7.6% from $6.06B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.52$3.56$3.44 - $3.78-1.12%Miss+10.3%250 up, 14 downOct 29, 2026$6.52B
    Jun 30, 2026$3.69$3.46$3.36 - $3.61+6.65%Beat+17.9%241 up, 1 downJul 30, 2026$6.59B
    Mar 31, 2026$2.60$2.98$2.86 - $3.07-12.75%Miss-8.5%240 up, 3 downApr 30, 2026$6.02B
    Dec 31, 2025$4.47$4.40$4.37 - $4.43+1.59%Beat+11.5%242 up, 1 downJan 29, 2026$7.17B
    Sep 30, 2025$3.19$3.13$3.05 - $3.16+1.92%Beat+11.1%261 up, 1 downOct 30, 2025$6.06B
    Jun 30, 2025$3.13$3.07$3.00 - $3.15+1.95%Beat+11.4%261 up, 2 downJul 31, 2025$6.02B
    Mar 31, 2025$2.84$2.73$2.65 - $3.14+4.03%Beat+13.6%261 up, 4 downMay 1, 2025$5.87B
    Dec 31, 2024$4.01$3.87$3.84 - $3.92+3.62%Beat+15.9%252 up, 1 downJan 28, 2025$6.44B
    Sep 30, 2024$2.87$2.77$2.71 - $2.96+3.61%Beat+16.7%272 up, 0 downOct 29, 2024$5.49B
    Jun 30, 2024$2.81$2.79$2.75 - $2.91+0.72%Beat+10.6%262 up, 0 downJul 30, 2024$5.42B
    Mar 31, 2024$2.50$2.36$2.28 - $2.48+5.93%Beat+16.8%240 up, 1 downApr 30, 2024$5.24B
    Dec 31, 2023$3.46$3.27$3.23 - $3.31+5.81%Beat+15.3%251 up, 0 downJan 30, 2024$5.82B
    Sep 30, 2023$2.46$2.44$2.34 - $2.53+0.82%Beat+16.0%251 up, 1 downNov 2, 2023$4.91B
    Jun 30, 2023$2.54$2.38$2.32 - $2.48+6.72%Beat+12.9%250 up, 0 downAug 3, 2023$5.00B
    Mar 31, 2023$2.14$2.00$1.96 - $2.11+7.00%Beat+8.6%251 up, 0 downMay 1, 2023$4.78B
    Dec 31, 2022$3.00$2.84$2.76 - $2.92+5.63%Beat+10.7%252 up, 0 downJan 31, 2023$5.20B
    Sep 30, 2022$2.12$2.23$2.14 - $2.34-4.93%Miss-3.6%251 up, 2 downOct 31, 2022$4.48B
    Jun 30, 2022$2.25$2.28$2.17 - $2.36-1.32%Miss0.0%221 up, 1 downJul 26, 2022$4.49B
    Mar 31, 2022$1.97$1.92$1.85 - $2.15+2.60%Beat+2.1%250 up, 1 downApr 28, 2022$4.28B
    Dec 31, 2021$2.71$2.72$2.69 - $2.80-0.37%Miss-3.6%250 up, 1 downJan 27, 2022$4.70B
    Sep 30, 2021$2.20$2.28$2.03 - $2.50-3.51%Miss+2.8%25N/AOct 28, 2021$4.16B
    Jun 30, 2021$2.25$2.13$1.88 - $2.26+5.63%Beat+251.6%27N/AJul 27, 2021$4.29B
    Mar 31, 2021$1.93$1.98$1.88 - $2.20-2.53%Miss+4.9%27N/AApr 27, 2021$3.95B
    Dec 31, 2020$2.81$2.55$2.34 - $2.68+10.20%Beat+12.9%27N/AJan 27, 2021$4.26B
    Sep 30, 2020$2.14$1.43$0.91 - $1.88+49.65%Beat+12.0%26N/AOct 29, 2020$3.74B
    Jun 30, 2020$0.64$0.57-$0.13 - $1.03+12.28%Beat-67.7%22N/AJul 30, 2020$2.76B
    Mar 31, 2020$1.84$1.74$0.85 - $2.08+5.75%Beat-2.1%15N/AApr 30, 2020$3.59B
    Dec 31, 2019$2.49$2.46$2.44 - $2.48+1.22%Beat+14.2%25N/AJan 28, 2020$4.13B
    Sep 30, 2019$1.91$1.90$1.86 - $1.92+0.53%Beat+13.0%26N/AOct 29, 2019$3.59B
    Jun 30, 2019$1.98$1.94$1.91 - $1.96+2.06%Beat+12.5%28N/AJul 25, 2019$3.65B
    Mar 31, 2019$1.88$1.84$1.82 - $1.87+2.17%Beat+11.9%29N/AApr 23, 2019$3.52B
    Dec 31, 2018$2.18$2.15$2.12 - $2.20+1.40%Beat+11.2%30N/AJan 29, 2019$3.80B
    Sep 30, 2018$1.69$1.68$1.64 - $1.72+0.60%Beat+11.2%26N/AOct 25, 2018$3.24B
    Jun 30, 2018$1.76$1.73$1.70 - $1.74+1.73%Beat+15.0%25N/AJul 24, 2018$3.32B
    Mar 31, 2018$1.68$1.60$1.58 - $1.64+5.00%Beat+13.5%26N/AApr 26, 2018$3.24B
    Dec 31, 2017$1.96$1.95$1.92 - $1.98+0.51%Beat+10.1%25N/AJan 30, 2018$3.47B
    Sep 30, 2017$1.52$1.50$1.42 - $1.55+1.33%Beat+9.4%26N/AOct 26, 2017$3.01B
    Jun 30, 2017$1.53$1.51$1.49 - $1.54+1.32%Beat+10.1%26N/AJul 27, 2017$3.01B
    Mar 31, 2017$1.48$1.43N/A+3.50%Beat+19.4%N/AN/AApr 25, 2017$2.96B
    Dec 31, 2016$1.78$1.76N/A+1.14%Beat+14.1%N/AN/AJan 24, 2017$3.16B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $13.63, up 11.8% from the year before. It was $5.80 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$13.63+11.8%
    Dec 31, 2024$12.19+15.0%
    Dec 31, 2023$10.60+13.5%
    Dec 31, 2022$9.34+2.8%
    Dec 31, 2021$9.09+22.3%
    Dec 31, 2020$7.43-10.0%
    Dec 31, 2019$8.26+13.0%
    Dec 31, 2018$7.31+12.6%
    Dec 31, 2017$6.49+11.9%
    Dec 31, 2016$5.80N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 20 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202610,16020
    2026Q2Jun 30, 20266,88617
    2026Q1Mar 31, 20269,89621
    2025Q4Dec 31, 20258,30620
    2025Q3Sep 30, 20255,79418
    2025Q2Jun 30, 20257,55216
    2025Q1Mar 31, 20259,80322
    2024Q4Dec 31, 20247,46115

    2026Q3 Earnings Call

    Opening remarks

    Kevin Lobo Chair and CEO Welcome to Stryker's third quarter earnings call. Joining me today are Preston Wells, CFO; and Nick Mead, Vice President of Investor Relations. Before I begin, I'd like to congratulate Spencer Stiles on his appointment as Stryker's next CEO. Spencer has spent nearly 3 decades at Stryker, helping shape our strategy, strengthen our culture and drive our growth. You will have additional opportunities to hear more from him at various investor events over the next few months, and I am confident we will come away with an even greater appreciation of his capabilities to lead Stryker into the future. For today's call, I'll provide an overview of our performance. Nick will then provide a brief M&A update, followed by Preston with additional details on financial results and guidance. We will then open the call to Q&A. Turning to our third quarter performance. Organic sales growth for the quarter was 7.7% with 9.1% growth in MedSurg and Neurotechnology and 5.9% growth in Orthopaedics. Our Endoscopy and Ortho Tech divisions delivered double-digit performances and Medical also delivered near double-digit growth. While we delivered solid growth in several businesses, our overall results fell short of our expectations. As Preston mentioned during the investor conference in September, we are facing challenges with our Hip and Knee and Peripheral Vascular businesses. Beginning with Hips and Knees, it is now clear that there is a market slowdown. In the U.S., we are seeing slower procedural growth amid affordability concerns from higher insurance premiums and deductibles. We are also observing increased pre-authorization denials, creating additional friction and delaying patient access to treatment. Europe and the Middle East have also remained soft amid regional disruption, strike-related delays and government funding decisions. In addition to the softer market, we have not been winning at our historical rate. 2026 has been an unusual year, marked by the cyber incident in the first quarter and an SAP implementation within our Orthopaedics businesses in July. This is the last of our businesses to go on to SAP. And while the system is functioning well, it has created a distraction for our teams and delayed our visibility of market conditions. Although Mako sales have been strong again this year, we are behind our expectations on new product sales from Mako RPS and Triathlon Gold. The feedback on these innovations is very positive, but the cyber incident and SAP implementation have impacted our commercial execution. We are taking actions to improve competitive conversions and new product adoption. Finally, as a leader in power tools, we are excited about bringing a power hip impaction solution to the market next year, addressing an important product gap in our hip portfolio.

    Frequently Asked Questions About SYK

    When is Stryker's next earnings date?

    Stryker's next earnings report is expected for Jan 27, 2027.

    Did SYK beat earnings estimates last quarter?

    No. Stryker reported EPS of $3.52 for the quarter ended Sep 30, 2026, below the $3.56 estimate by 1.12%.

    What EPS do analysts expect from SYK next quarter?

    The consensus EPS estimate for Stryker for the quarter ending Dec 31, 2026 is $5.06 from 28 analysts, with estimates from $4.55 to $5.30.

    How often does SYK beat earnings estimates?

    Stryker beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +0.74%.